Mode
Text Size
Log in / Sign up
N/A N=36 Treatment

Validation of Safety and Efficacy for Night Shift Therapy

Obstructive Sleep Apnea

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcome: Primary: Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events — 100 Percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Deliver therapy when the supine position is detected (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Advanced Brain Monitoring, Inc.
Primary completion
Feb 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Who Completed the Study at 4 Weeks Without Adverse Events
100
PRIMARY
Evaluate Efficacy Based on a Change in Obstructive Sleep Apnea (OSA) Severity as a Result of Therapy
83
SECONDARY
Confirmation That Night Shift Accurately Detects Supine Position
91; 93
SECONDARY
Evaluate Whether Night Shift Disrupts Sleep Such That Users Are Non-compliant
96
SECONDARY
Evaluate Whether Patients Adapt and Sleep Through the Position Therapy Feedback
97
SECONDARY
Evaluate Efficacy by Confirming Position Therapy Reduces Daytime Somnolence in Patients With Positional OSA
50
SECONDARY
Evaluate Impact of Positional Therapy on Quality of Life Scores
57
SECONDARY
Assess the Accuracy of Night Shift's Detection of Sleep vs. Wake
88.7; 91.3; 55.0; 61.2
SECONDARY
Assess the Accuracy of Night Shift's Measurement of Total Sleep Time
98
SECONDARY
Assess the Accuracy of Night Shift Measurement of Sleep Efficiency
92

Summary

The purpose of this study is to assess the accuracy of Night Shift in the detection of supine sleep and efficacy of vibro-tactile feedback in restricting supine sleep.

Eligibility Criteria

The inclusion criteria are:

  • be between the age of 18 and 75 years,
  • have been diagnosed with Obstructive Sleep Apnea (OSA) during polysomnography at a designated sleep center within 4 months of their enrollment,
  • have not received treatment with any OSA therapy for more than 3 days within the past month,
  • have an overall Apnea-Hypopnea Index (AHI) > 10 and hypopneas requiring >3% oxygen desaturation,
  • having a non-supine Apnea-Hypopnea Index (AHI) 1.5,
  • had an Epworth Sleepiness Score of 5 or more at the time of diagnosis and at the start of therapy,
  • Change in weight of no more than 5 pounds since the diagnostic PSG
  • access to a computer and the Internet
  • sleep is sometime between 8 P.M. to 9 A.M. Monday through Friday in the same bed

Exclusion Criteria

  • Neck, back or should pain which would impact ability to sleep laterally each night
  • Body mass index > 35
  • suffering from neurological disorders which result in ticks or tremors
  • diagnosed with congestive heart failure or chronic obstructive pulmonary disease
  • suffered from a stroke within the previous 12 months
  • taking or planning to take narcotic medications
  • unfamiliar with use of internet browsers
  • travel (i.e., foreign or cruise ship) which would limit internet or mail access
  • planned medical procedures (e.g., surgery) which would limit device use during the scheduled 30-day study period or introduce the need for narcotic pain medications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02032706). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search